Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Sep;53(9):1595-1601.
doi: 10.1111/imj.15830. Epub 2022 Nov 8.

Guideline-based audit of the hospital management of heart failure with reduced ejection fraction

Douglas Drak  1 , Jordan Fulcher  1   2   3 , Jens Kilian  4 , James J H Chong  1   5   6 , Rominder Grover  7 , Andrew P Sindone  8 , Mark Adams  1   2 , Jo-Dee Lattimore  1   2 , Anthony C Keech  1   2   3
Affiliations
Comment

Guideline-based audit of the hospital management of heart failure with reduced ejection fraction

Douglas Drak et al. Intern Med J. 2023 Sep.

Abstract

Background: Heart failure is a major burden in Australia in terms of morbidity, mortality and healthcare expenditure. Multiple evidence-based therapies are recommended for heart failure with reduced ejection fraction (HFrEF), but data on physician adherence to therapy guidelines are limited.

Aim: To compare use of HFrEF therapies against current evidence-based guidelines in an Australian hospital inpatient population.

Methods: A retrospective review of patients admitted with a principal diagnosis of HFrEF across six metropolitan hospitals in Sydney, Australia, between January 2015 and June 2016. Use of medical and device therapies was compared with guideline recommendations using individual patient indications/contraindications. Readmission and mortality data were collected for a 1-year period following the admission.

Results: Of the 1028 HFrEF patients identified, 39 were being managed with palliative intent, leaving 989 patients for the primary analysis. Use of beta-blockers (87.7% actual use/93.6% recommended use) and diuretics (88.4%/99.3%) was high among eligible patients. There were large evidence-practice gaps for angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEI/ARB; 66.4%/89.0%) and aldosterone antagonists (41.0%/77.1%). In absolute terms, use of these therapies each increased by over 11% from admission. Ivabradine (11.5%/21.2%), automated internal cardiac defibrillators (29.5%/66.1%) and cardiac resynchronisation therapy (13.1%/28.7%) were used in a minority of eligible patients. Over the 1-year follow-up period, the mortality rate was 14.8%, and 44.2% of patients were readmitted to hospital at least once.

Conclusion: Hospitalisation is a key mechanism for initiation of HFrEF therapies. The large evidence-practice gaps for ACEI/ARB and aldosterone antagonists represent potential avenues for improved HFrEF management.

Keywords: evidence-practice gap; guideline adherence; heart failure; systolic.

PubMed Disclaimer

Comment on

References

    1. Sindone AP, Haikerwal D, Audehm RG, Neville AM, Lim K, Parsons RW et al. Clinical characteristics of people with heart failure in Australian general practice: results from a retrospective cohort study. ESC Heart Fail 2021; 8: 4497-505.
    1. Krum H, Abraham WT. Heart failure. Lancet 2009; 373: 941-55.
    1. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397-402.
    1. Ødegaard KM, Hallén J, Lirhus SS, Melberg HO, Halvorsen S. Incidence, prevalence, and mortality of heart failure: a nationwide registry study from 2013 to 2016. ESC Heart Fail 2020; 7: 1917-26.
    1. McMurray JJV, Stewart S. The burden of heart failure. Eur Heart J Suppl 2002; 4: D50-8.

MeSH terms

Substances

LinkOut - more resources